Streetbeat News

Partnerships

ENVB

Enveric Biosciences, Inc. (NASDAQ:ENVB) shares surged after announcing three non-binding term sheets with an undisclosed biotech company for out-licensing compounds, potentially earning up to $200 million plus royalties. The deals are contingent on IND approvals and successful Phase I-III testing. CEO Joseph Tucker highlighted the potential revenue and value creation from Enveric's discovery platforms. Additionally, ENVB has an average 1-year price target of $10, indicating a significant upside.

Portfolio Pulse from Erica Kollmann

February 29, 2024 | 4:16 pm

BRAXF

BWVI

CMPS

In the Benzinga Psychedelics Podcast, Zappy Zapolin discusses the future of psychedelics, highlighting the industry's potential mainstream breakthrough in 2024 with federal legalization of MDMA for PTSD, psychedelics legalization campaigns, and COMPASS Pathways' commercialization. Zapolin, involved with companies like KetaMD (acquired by Braxia Scientific, OTC:BRAXF) and Psycheceutical Bioscience (OTC:BWVI), also launches guided psychedelic retreats, emphasizing the importance of medical supervision in therapy.

Portfolio Pulse from Lara Goldstein

February 29, 2024 | 4:04 pm

F

TSLA

Ford Motor Company (NYSE:F) has announced that its electric vehicle (EV) customers, specifically those owning Ford F-150 Lightning and Mustang Mach-E, now have access to Tesla Inc's (NASDAQ:TSLA) Supercharger network. This access includes over 15,000 Tesla Superchargers, effectively doubling the charging options for Ford's EV customers. The partnership, which was first announced in May 2023, allows Ford EV owners to use a fast-charging adapter for free until June 30, 2024, after which it will cost $230. This collaboration is seen as a significant step towards improving EV infrastructure and reducing barriers to EV adoption.

Portfolio Pulse from Chris Katje

February 29, 2024 | 3:43 pm

AAPL

MARA

TSLA

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin have seen significant gains, leading to $750M in liquidations. Gemini will refund $1.1B to Earn Program customers. Apple's shareholders rejected a proposal for AI transparency. Marathon Digital's shares fell despite Bitcoin's rally. Dogecoin's market cap surpassed MicroStrategy and Robinhood. Analysts predict a 600% surge in Dogecoin's price. The ETF tracking Congressional Democrats' trades outperformed the S&P 500. US markets show uncertainty ahead of inflation data. Goldman Sachs CEO and Peter Schiff express concerns about the US economy. SEC investigates OpenAI CEO, and Apple faces a vote on AI transparency. Tesla is accused of polluting Berlin's water, and GXO Logistics leads a bidding war for Wincanton.

Portfolio Pulse from Akanksha Bakshi

February 29, 2024 | 2:45 pm

SNX

Indusface has partnered with TD SYNNEX to offer managed web application and API protection solutions to Managed Service Providers (MSPs) serving SMEs. This partnership aims to provide affordable enterprise-class security solutions.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:34 pm

VZ

Verizon has announced a partnership with the U.S. military to engage in extreme training exercises aimed at enhancing their preparedness for responding to natural disasters. This collaboration is designed to improve the resilience and response capabilities of both Verizon's infrastructure and personnel when faced with emergencies.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:31 pm

PUBM

Wpromote has chosen PubMatic as its preferred partner, granting Wpromote clients access to PubMatic's extensive publisher inventory. This partnership is expected to enhance the advertising capabilities of Wpromote's clients by providing them with a wider range of high-quality ad inventory options.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:13 pm

HTCR

HeartCore Enterprises, Inc. (HTCR) has entered into a Go IPO contract with Jyo, expecting to generate $700,000 in initial fees. Additionally, HTCR will receive a warrant to acquire 2% of Jyo's common stock, marking a significant development for the company.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:09 pm

AMIX

Autonomix has signed key clinical agreements as final preparations to begin a proof-of-concept human clinical trial in March 2024, targeting the pancreatic cancer market with transvascular RF ablation. Patient enrollment is expected to start imminently.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:01 pm

NVDA

RVSN

Rail Vision has become a member of the NVIDIA Metropolis Partner Program, aiming to leverage NVIDIA's AI technologies to enhance its rail safety and monitoring solutions.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 2:00 pm